2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N2180
    Pinoresinol dimethyl ether 29106-36-3 ≥99.0%
    Pinoresinol dimethyl ether ((+)-Eudesmin) is a non-phenolic furofuran lignan isolated from Magnolia biondii with neuritogenic activity. Pinoresinol dimethyl ether ((+)-Eudesmin) can induce neuritis outgrowth from PC12 cells by stimulating up-stream MAPK, PKC and PKA pathways.
    Pinoresinol dimethyl ether
  • HY-N2320
    Physostigmine hemisulfate 64-47-1 ≥99.0%
    Physostigmine hemisulfate (Eserine hemisulfate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine hemisulfate can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine hemisulfate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine hemisulfate is also an antidote for anticholinergic poisoning.
    Physostigmine hemisulfate
  • HY-N3017
    Artemitin 479-90-3 99.97%
    Artemitin is a flavonoid neuroanesthetic agent with moderate cytotoxicity. Artemitint has selective inhibitory activity against Meth-A sarcoma cells with an ED50 of 5-10 μg/mL, and has no significant effect on LLC lung cancer cells. Artemitin exerts anticancer activity by affecting cell proliferation signaling pathways, and also has potential anti-inflammatory and neuroprotective effects. Artemitin exhibits a dose-dependent antinociceptive effect in the mouse hot plate test, with an ED50 of 1.6 μg/kg, and has analgesic activity.
    Artemitin
  • HY-N6866
    Gomisin N 69176-52-9 ≥99.0%
    Gomisin N is an orally active lignan compound. Gomisin N can be isolated from Schisandra chinensis. Gomisin N induces Apoptosis in a variety of cells. Gomisin N activates AMPK, Akt, MAPK/ERK, Nrf2, caspase-3 and PARP-1. Gomisin N inhibits GSK3β, nitric oxide (NO), and proinflammatory cytokines (IL-1β, IL-6, TNF-α). Gomisin N has anti-inflammatory, antioxidant, anti-obesity, anti-diabetic, and anti-melanogenesis activities. Gomisin N has anti-tumor activity against cervical cancer and liver cancer. Gomisin N improves Alzheimer's disease.
    Gomisin N
  • HY-N7028
    Withanolide A 32911-62-9 98.22%
    Withanolide A is an orally active extract from the Indian herb Ashwagandha. Withanolide A can induce apoptosis. Withanolide A has anti-inflammatory and antitumor activity. Withanolide A can be used in the study of neurodegenerative diseases.
    Withanolide A
  • HY-N8572
    3',4'-Dimethoxyflavone 4143-62-8 98.55%
    3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects.
    3',4'-Dimethoxyflavone
  • HY-N8723
    (1′S,2′S)-Nicotine-1'-oxide 51095-86-4 ≥99.0%
    (1′S,2′S)-Nicotine-1'-oxide is an alkaloid N-oxide from the leaves, stems and roots of Nicotiana tabacum.
    (1′S,2′S)-Nicotine-1'-oxide
  • HY-NP001
    Cationic Bovine Serum Albumin
    Cationic Bovine Serum Albumin is a bovine serum albumin (BSA) modified with excess ethylenediamine, which has enhanced immunogenicity compared to native BSA. Positively charged primary amines block all negatively charged carboxyl groups, making Cationic Bovine Serum Albumin a cationic protein. Cationic Bovine Serum Albumin has remarkable neuroprotective effects on ischemic stroke when in combination with Tanshinone IIA (HY-N0135) .
    Cationic Bovine Serum Albumin
  • HY-P0257
    Astressin 170809-51-5 98.93%
    Astressin is a potent corticotropin releasing factor (CRF) antagonist.
    Astressin
  • HY-P1203
    BIM-23056 150155-61-6 99.98%
    BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively.
    BIM-23056
  • HY-P2878
    Phosphodiesterase I 9025-82-5
    Phosphodiesterase I (PDE) is an enzyme that can catalyze the hydrolysis of the 3' ring phosphate bond of cyclic nucleotides, and is often used in biochemical research. Phosphodiesterase I acts as an important regulator of signal transduction mediated by the second messenger molecules cAMP and cGMP. According to their specificity to cyclic nucleotides, they can also be divided into different types, such as PDE1-PDE11, which also have certain potential in various diseases.
    Phosphodiesterase I
  • HY-P5905
    Citrullinated amyloid-β (1-42) peptide (human)
    Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets.
    Citrullinated amyloid-β (1-42) peptide (human)
  • HY-Y1117
    Melamine 108-78-1 ≥98.0%
    Melamine is an orally active inducer of Apoptosis. Melamine induces animal disease models. Melamine affects the activity of Sertoli cell and can be used for research on male reproductive function. Melamine also has neurotoxicity and nephrotoxicity. Melamine induces cognitive impairment and acute kidney injury models. Melamine can also be used to induce bladder cancer and urinary stone models.
    Melamine
  • HY-100080
    A-887826 1266212-81-0 99.76%
    A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC50 of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo.
    A-887826
  • HY-100665
    Dehydroaripiprazole 129722-25-4 99.66%
    Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole (HY-14546) and dopamine D2/D3 receptor partial agonist. Dehydroaripiprazole also has certain affinity for serotonin 5-HT1A, 5-HT2A and 5-HT2B receptors. Dehydroaripiprazole has antipsychotic activity equivalent to Aripiprazole.
    Dehydroaripiprazole
  • HY-101315
    AHN 1-055 hydrochloride 202646-03-5 99.96%
    AHN 1-055 hydrochloride is a dopamine uptake inhibitor, with an IC50 of 71 nM. AHN 1-055 hydrochloride binds with high affinity to the dopamine transporter (DAT).
    AHN 1-055 hydrochloride
  • HY-101478
    Fenobam 57653-26-6 ≥99.0%
    Fenobam is a selective and orally active mGluR5 antagonist (IC50=84 nM) that can penetrate the blood-brain barrier. Fenobam shows the Kd values of 54 nM and 31 nM on rat and human recombinant mGlu5 receptors, respectively. Fenobam has anxiolytic activity, inhibits self-administration behavior in mice, and induces apoptosis in cancer cells. Fenobam can be used for research on neurological diseases, cancer and drug addiction.
    Fenobam
  • HY-101528
    IDRA 21 22503-72-6 99.33%
    IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging.
    IDRA 21
  • HY-101869
    MK-0343 233275-76-8 ≥99.0%
    MK0343 (MRK-409) is an orally bioavailable GABAA receptor subtype-selective partial agonist. MK0343 is a non-sedating anxiolytic.
    MK-0343
  • HY-103060
    KLH45 1632236-44-2 ≥98.0%
    KLH45 is a potent and selective DDHD2 inhibitor, with an IC50 of 1.3 nM.
    KLH45
Cat. No. Product Name / Synonyms Application Reactivity